Product Description
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Brazil | Chile | Colombia | Finland | Germany | Ireland | Italy | Peru | Portugal | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: University of Sydney
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
A Trial of Nilvadipine in Mild to Moderate Alzheimer's disease | P3 |
Completed |
Alzheimer Disease |
2016-12-16 |
|
NILVAD | P3 |
Completed |
Alzheimer Disease |
2016-12-16 |
|
St. James's Hospital Nivadil Trial | P4 |
Completed |
Alzheimer Disease |
2009-03-03 |